Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 12/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379673 | 1.00 | MEN1 (0.46) | MEN1KMT2AATMBACE1 | |
| SCHEMBL3379680 | 1.00 | MEN1 (0.46) | MEN1KMT2AATMBACE1 | |
| SCHEMBL3382127 | 0.98 | MEN1 (0.47) | MEN1KMT2AATMBACE1 | |
| SCHEMBL3382121 | 0.98 | MEN1 (0.47) | MEN1KMT2AATMBACE1 | |
| SCHEMBL3382125 | 0.98 | MEN1 (0.47) | MEN1KMT2AATMBACE1 | |
| SCHEMBL3383475 | 0.91 | CTSD (0.47) | MEN1KMT2A | |
| SCHEMBL3385905 | 0.91 | CTSD (0.47) | MEN1KMT2A | |
| SCHEMBL3383468 | 0.91 | CTSD (0.47) | MEN1KMT2A | |
| SCHEMBL3386518 | 0.91 | CTSD (0.47) | MEN1KMT2A | |
| SCHEMBL3385911 | 0.91 | CTSD (0.47) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8183231-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1765850-B1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMA INC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | MEN1 1371/4885KMT2A 1971/4885ATM 2473/4885 |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | MEN1 1371/4885KMT2A 1971/4885ATM 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.